Trials / Enrolling By Invitation
Enrolling By InvitationNCT07376629
A Study of HB0025 Plus Nab-paclitaxel as First Line Therapy for TNBC
A Phase II Study of HB0025 in Combination With Nab-Paclitaxel as First Line Therapy for Unresectable, Locally Advanced or Metastatic Triple-negative Breast Cancer.
- Status
- Enrolling By Invitation
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- Sponsor
- Huabo Biopharm Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This trial is a Phase II study. The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of HB0025 administered with chemotherapy in participants with locally advanced or metastatic triple-negative breast cancer (TNBC) who have not received prior systemic therapy for metastatic breast cancer (mBC).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HB0025 20 mg/kg plus nab-paclitaxel | HB0025 20 mg/kg |
| DRUG | HB0025 10 mg/kg plus nab-paclitaxel | HB0025 10 mg/kg |
Timeline
- Start date
- 2025-08-14
- Primary completion
- 2027-01-15
- Completion
- 2027-01-15
- First posted
- 2026-01-29
- Last updated
- 2026-01-29
Locations
23 sites across 1 country: China
Source: ClinicalTrials.gov record NCT07376629. Inclusion in this directory is not an endorsement.